A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme

PURPOSE: Irinotecan is a cytotoxic agent with activity against gliomas. Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM). To evaluate the combination of thalidomide and irinotecan, we conducted a phase II trial in adults with newly-diagnosed or...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Fadul, Camilo E., Kingman, Linda S., Meyer, Louise P., Cole, Bernard F., Eskey, Clifford J., Rhodes, C. Harker, Roberts, David W., Newton, Herbert B., Pipas, J. Marc
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3885231/
https://ncbi.nlm.nih.gov/pubmed/18661102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-008-9655-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items